Moody's Investors Service

Patent cliffs face BMS, Merck, Pfizer but all can pull off M&A

BMS, Pfizer and Merck will face patent cliff exposure later in this decade but all have the financial flexibility to compensate with M&A, Moody's says

Kevin Dunleavy Jun 21, 2022 4:14pm